General Information of Drug (ID: DM4G09S)

Drug Name
SB-505124 Drug Info
Synonyms
SB-505124; 694433-59-5; SB505124; SB 505124; 2-(4-(benzo[d][1,3]dioxol-5-yl)-2-tert-butyl-1H-imidazol-5-yl)-6-methylpyridine; CHEMBL226838; 2-[4-(1,3-Benzodioxol-5-yl)-2-(tert-butyl)-1H-imidazol-5-yl]-6-methylpyridine; 2-[5-(1,3-Benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazol-4-yl]-6-methylpyridine; 2-[4-(2H-1,3-benzodioxol-5-yl)-2-tert-butyl-1H-imidazol-5-yl]-6-methylpyridine; MLS006010969; SCHEMBL373422; GTPL6049; CTK8E3615; KS-00000XPS; EX-A217; DTXSID50431926; AOB1766; AOB5688; MolPort-021-804-897; CHEBI:100922
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9858940
ChEBI ID
CHEBI:100922
CAS Number
CAS 694433-59-5
TTD Drug ID
DM4G09S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2157299 DMP8HW1 Arteriosclerosis BD40 Phase 2/3 [3]
TEW-7197 DM2LBC3 Myeloproliferative neoplasm 2A20 Phase 2 [4]
Metelimumab DMENFD6 Scleroderma 4A42 Phase 1/2 [5]
TP-0184 DMJVZBC Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
P-2745 DMJ3PNS Chronic myelogenous leukaemia 2A20.0 Phase 1 [7]
LY3200882 DMQP6VB Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
PF-06952229 DMDQJEZ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
SB-431542 DM0YOXQ Pulmonary fibrosis CB03.4 Preclinical [10]
SM-16 DMHXJV2 Fibrosis GA14-GC01 Terminated [11]
LF-984 DMIYMS2 Fibrosis GA14-GC01 Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TGF-beta receptor type I (TGFBR1) TTP4520 TGFR1_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6049).
2 Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4228-4232 (2010).
3 Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
6 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
7 Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
10 Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
11 TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
12 US patent application no. 2013,0028,978, Compositions and methods for wound treatment.